NFLD to continue PolyHeme Phase III

Northfield (NFLD) said that for the second time, an independent data monitoring committee (IDMC) recommended continuing the Phase III ambulance trial of PolyHeme red blood cell substitute without any modification. NFLD said the recommendation was based on mortality and serious adverse data in the first 120 patients enrolled in the study. The trial in up to 720 severely injured and bleeding trauma patients is measuring survival at 30 days. The trial continues to enroll patients. ...